# A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

Study · id `cardio:ct-nct06616974` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06616974](<https://clinicaltrials.gov/study/NCT06616974>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06616974

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 191 participants.

## Technical summary

Registry record NCT06616974. Randomized; double masking; primary purpose treatment. Start 2024-09-04 (actual); primary completion 2026-11-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 191 participants (planned count; ClinicalTrials.gov record NCT06616974, source copy `cardio:ctgov-nct06616974-2026-07-07`, retrieved 2026-10-31)
- Started: 2024-09-04 (actual) (ClinicalTrials.gov record NCT06616974, source copy `cardio:ctgov-nct06616974-2026-07-07`, retrieved 2026-10-31)
- Primary completion: 2026-11-24 (anticipated) (ClinicalTrials.gov record NCT06616974, source copy `cardio:ctgov-nct06616974-2026-07-07`, retrieved 2026-10-31)
- Completion: 2027-01-05 (anticipated) (ClinicalTrials.gov record NCT06616974, source copy `cardio:ctgov-nct06616974-2026-07-07`, retrieved 2026-10-31)
- Countries: United States; Armenia; Australia; Austria; Belgium; Bulgaria; Georgia; Germany; Latvia; Moldova; New Zealand; Poland; Portugal; Romania; Serbia; Spain; Ukraine (ClinicalTrials.gov record NCT06616974, source copy `cardio:ctgov-nct06616974-2026-07-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06616974-2026-07-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
- Condition: Pulmonary Hypertension
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Drug): TX000045- Dose A
- Intervention (Drug): TX000045- Dose B
- Intervention (Drug): Placebo
- Lead sponsor: Tectonic Therapeutic
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 4d4951a251c8ff5bbf0e980be9b00c4d7d42676d9087f73fbc11ffaec70c17e3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
